Articles by Claire Harrison, MD, FRCP, FRCPath
An expert's insights on the latest advancements in MF treatment presented at the ASH 2024 meeting.
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.